What a difference a decade and a half makes in breast cancer treatment advances:
| HRR (%) |
|---|
| Yearly interval | 0-1 | 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | 6-7 | 7-8 | 8-9 |
| Cohort 1 | 4.7±0.4 | 8.8±0.5 | 6.8±0.5 | 5.0±0.4 | 4.2±0.4 | 3.7±0.4 | 3.0±0.4 | 3.1±0.4 | 1.8±0.3 |
| Cohort 2 | 2.7±0.2 | 4.0±0.3 | 3.6±0.2 | 2.6±0.2 | 2.0±0.2 | 1.3±0.2 | 1.2±0.2 | 1.2±0.3 | 0.3±0.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ER+/HER2+ | C1
C2 | 6.7±1.7 | 13.7±2.5 | 12.1±2.6 | 21.6±2.6 | 6.9±2.2 | 3.7±1.7 | 3.2±1.6 | 4.3±1.9 | 2.8±1.6 |
| 2.5±0.6 | 3.1±0.7 | 3.9±0.7 | 3.0±0.7 | 2.7±0.7 | 1.8±0.6 | 0.3±0.3 | 0.7±0.7 | 0 |
| ER-/HER2+ | C1
C2 | 13.9±2.5 | 23.6±3.6 | 17.0±3.4 | 7.8±2.5 | 6.8±2.4 | 2.7±1.6 | 1.8±1.3 | 1.9±1.3 | 2.0±1.4 |
| 4.0±0.9 | 8.3±1.3 | 5.5±1.1 | 3.0±0.8 | 1.3±0.6 | 0.3±0.3 | 0 | 1.7±1.2 | 0 |
Please note this is a Canadian study. Also information regarding specific treatment is not given. A search of the internet states that Herceptin was approved in Canada for early breast cancer in mid 2005. If so these number might have a large group of Her2 positive patients that did not receive Herceptin in the C2 group, 2004 - 2008. I would suspect that the current numbers are even better with adjuvant Herceptin for early stage.
With advances in treatment, such as neo-adjuvant Perjeta in the States - we are a group of women that are truly blessed with the results of cancer research.